Unable to write in log file ../../bases/logs/gimorg/logerror.txt Seroconversion stages COVID19 into distinct pathophysiological states. | Elife;102021 03 16. | MEDLINE
Seroconversion stages COVID19 into distinct pathophysiological states.
Galbraith, Matthew D; Kinning, Kohl T; Sullivan, Kelly D; Baxter, Ryan; Araya, Paula; Jordan, Kimberly R; Russell, Seth; Smith, Keith P; Granrath, Ross E; Shaw, Jessica R; Dzieciatkowska, Monika; Ghosh, Tusharkanti; Monte, Andrew A; D'Alessandro, Angelo; Hansen, Kirk C; Benett, Tellen D; Hsieh, Elena Wy; Espinosa, Joaquín M.
  • Galbraith MD; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Kinning KT; Department of Pharmacology, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Sullivan KD; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Baxter R; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Araya P; Department of Pediatrics, Division of Developmental Biology, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Jordan KR; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Russell S; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Smith KP; Department of Immunology and Microbiology, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Granrath RE; Data Science to Patient Value, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Shaw JR; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Dzieciatkowska M; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Ghosh T; Linda Crnic Institute for Down Syndrome, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Monte AA; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • D'Alessandro A; Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, United States.
  • Hansen KC; Department of Emergency Medicine, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Benett TD; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Hsieh EW; Department of Biochemistry and Molecular Genetics, University of Colorado Anschutz Medical Campus, Aurora, United States.
  • Espinosa JM; Department of Pediatrics, Sections of Informatics and Data Science and Critical Care Medicine, University of Colorado Anschutz Medical Campus, Aurora, United States.
Elife ; 102021 03 16.
Article in English | MEDLINE | ID: covidwho-1136623
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
COVID19 is a heterogeneous medical condition involving diverse underlying pathophysiological processes including hyperinflammation, endothelial damage, thrombotic microangiopathy, and end-organ damage. Limited knowledge about the molecular mechanisms driving these processes and lack of staging biomarkers hamper the ability to stratify patients for targeted therapeutics. We report here the results of a cross-sectional multi-omics analysis of hospitalized COVID19 patients revealing that seroconversion status associates with distinct underlying pathophysiological states. Low antibody titers associate with hyperactive T cells and NK cells, high levels of IFN alpha, gamma and lambda ligands, markers of systemic complement activation, and depletion of lymphocytes, neutrophils, and platelets. Upon seroconversion, all of these processes are attenuated, observing instead increases in B cell subsets, emergency hematopoiesis, increased D-dimer, and hypoalbuminemia. We propose that seroconversion status could potentially be used as a biosignature to stratify patients for therapeutic intervention and to inform analysis of clinical trial results in heterogenous patient populations.
Subject(s)
Keywords
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Seroconversion / SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: ELife.65508

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Seroconversion / SARS-CoV-2 / COVID-19 Type of study: Observational study / Prognostic study / Randomized controlled trials Limits: Humans Language: English Year: 2021 Document Type: Article Affiliation country: ELife.65508